Radoslaw Parma

Interventional Cardiologist 🇵🇱🇪🇺 | FESC FSCAI

[THT @THTconference]

5+ hours of hands-on TAVI CT planning on Philips HeartNavigator, VesselNavigator and AVW.

Sat 14 Nov, Katowice, 09:00–16:00. Faculty: @JoannaNawara and @RafalWolny. 20 places, course in Polish.

https://t.co/nQefVE60Ic

#TAVI #CardiacCT
cc @aisnptk @PTKardio @PCRonline

[PCRonline 🫀 @PCRonline]

⌛ Still putting the finishing touches on your submission? The deadline has been extended to 19 October!

Submit your Clinical Case, Scientific Abstract or Late-Breaking Trial and help shape the #PCRTokyo Programme.

🔗https://t.co/5ulTNAy5zG

@dmylotte @OhnoTuri @didier_tchetche

[Radoslaw Parma @parma]

Lifetime TAVI starts with the planning CT.

Thank you to everyone who spent Saturday at the workstation in Warsaw and to the @CVPrev_Interv organizers for staying together!

Next stop: Katowice, Saturday, echo for M-TEER and T-TEER.

[THT @THTconference]

Thank you, Warsaw!

TAVI CT Express at @CVPrevInterv today, hands-on with @RafalWolny and @BartoszRymuza.

Next stop: THT Imaging in Katowice, Sat 17 Oct.
Echo patient selection for M-TEER and T-TEER by Piotr Pysz & Patrycjusz Stokłosa.

Register by Fri 16 Oct: https://t.co/4Hpp78kowS

#TAVI #TEER

[Radoslaw Parma @parma]

Hands-on in Warsaw today: TAVI CT Express by @THTconference at Prevention & Intervention 2026.

Two 2-hour sessions, one 3mensio workstation per participant: access, annulus sizing, coronary heights, commissural alignment, TAV-in-TAV feasibility.

Faculty: Rafał Wolny, Bartosz Rymuza.

[THT @THTconference]

Today at @CVPrevInterv: TAVI CT Express at Focus Hotel Premium Warszawa.

Sessions at 11:00 and 14:00, hands-on in 3mensio with @RafalWolny and @BartoszRymuza. One question runs through both: what does this CT tell us about the second valve, not only the first?

#TAVI #CardiacCT

[THT @THTconference]

Today at @CVPrevInterv: TAVI CT Express at Focus Hotel Premium Warszawa.

Sessions at 11:00 and 14:00, hands-on in 3mensio with @RafalWolny and @BartoszRymuza. One question runs through both: what does this CT tell us about the second valve, not only the first?

#TAVI #CardiacCT

[PCRonline 🫀 @PCRonline]

Good news: the #PCRTokyo submission deadline has been extended to 12 October! ⌛

Submit your Clinical Cases, Scientific Abstracts or Late-Breaking Trials.

🏆 Two awards are up for grabs – winners will present at #PCRLV 2027 🇬🇧 and attend PCR Tokyo Valves 2028 with registration, travel and accommodation covered 🇯🇵

🔗 Submit: https://t.co/qx4GreNfhN

🗓️ #PCRTokyo 19-21 February 2027

@OhnoTuri @dmylotte @didier_tchetche

[Radoslaw Parma @parma]

TEER decisions start on the echo machine. Real cases, Katowice 🇵🇱.

[THT @THTconference]

The outcome of edge-to-edge repair is largely decided before the patient reaches the cath lab.

Patient Selection for M-TEER and T-TEER: a half-day, case-based echo workshop from THT Imaging and @aisnptk.
1. Clinical qualification
2. TTE: mechanism, grading, ventricular function
3. TEE: acquisition, regurgitation, valve area, septum
4. Procedure planning

Sat 17 Oct, 08:50-12:50, Hotel Monopol, Katowice. Faculty: Patrycjusz Stokłosa and Piotr Pysz.
25 places, 100 PLN, taught in Polish. Register by Fri 16 Oct: https://t.co/4Hpp78kWmq

Warsztaty po polsku, zapisy do piątku 16 października.

Educational support: @GEHealthCare and @AbbottNews. Partners have no influence on the programme.

#TEER #EchoFirst

[Radoslaw Parma @parma]

Lifetime TAVI starts with the planning CT.
Two hands-on sessions on Saturday in Warsaw 🇵🇱.

[THT @THTconference]

As TAVI moves to younger patients, the planning CT has to answer a second question: will a second valve fit one day?

TAVI CT Express, this Saturday at @CVPrevInterv in Warsaw. Two hours hands-on in 3mensio with @RafalWolny and @BartoszRymuza:
1. Annulus sizing and prosthesis selection
2. Root, calcium and membranous septum
3. Coronary access and commissural alignment
4. Vascular access

Sessions at 11:00 and 14:00. Free, 22 places each, taught in Polish.
Register by Fri 9 Oct, 23:59: https://t.co/cLXyDdn1Is

Bezpłatne warsztaty po polsku, zapisy do piątku do 23:59.

3mensio workstations by mTree Medical Solutions. Educational support: @EdwardsLifesci and @aisnptk.

#TAVI #CardiacCT

[Radoslaw Parma @parma]

@EIJCaseReports @aayshacader Congratulations to the Editorial Team and all the authors!

[EuroIntervention Case Reports @EIJCaseReports]

Issue 1 of EuroIntervention Case Reports is now complete! 📖

Explore the peer-reviewed cases published in our first issue and the clinical lessons they offer across complex procedures, complications, imaging and more.

🔗 Explore Issue 1: https://t.co/SEQpptS2AQ

[Radoslaw Parma @parma]

It is a joy to share the experience of our 🇵🇱 Polish Heart Team in Katowice.

IC & CS friendship helped us develop a standardized approach to #transcarotid #TAVI procedures.

Hope it helps patients needing alternative access to #TAVR and TAVR operators mastering this technique.

Authors:
@WWojakowski Damian Hudziak Radoslaw Gocol
for Katowice Heart Team

@PCRonline @aisnptk @PTKardio #StructuralHeart

[PCRonline 🫀 @PCRonline]

My #InterventionalCardiology Toolkit 🧰⚙️🔧: a detailed step-by-step guide to Transcarotid #TAVI

🔗https://t.co/YFy2mp1FVU

When transfemoral access is off the table, transcarotid TAVI offers a direct route to the valve, but success depends on meticulous planning and execution.

Based on > 200 cases, this practical My Toolkit walks through every step, including side selection, carotid exposure, cerebral protection, delivery-system control and closure.

Submitted by @parma , Radoslaw Gocol, Wojtek Wojakowski & Damian Hudziak, and reviewed by @modine_thomas .

#TAVR #CardioEd

@kiadeb87 @sbrugaletta @fjsawaya

[Radoslaw Parma @parma]

@EIJCaseReports @EuroInterventio Transcarotid ☀️

[Murmur MD @Murmur_MD]

What happens when an asymptomatic AS patient qualifies for TAVR today?

Breaking down Medicare coverage, CED requirements, and the current path forward. #TAVR #CardioTwitter

[Radoslaw Parma @parma]

Just accepted in JACC: Cardiovascular Interventions: a proposed common language for valve-in-valve TAVR, harmonizing procedural planning across TAV-in-SAV and TAV-in-TAV.

🔗 https://t.co/83Ucn0Czbg

Thank you @SyedZaidMD, @miho_fukui_, @bapat_savrtavr, @GilbertTangMD and Ole De Backer for this collaboration. 🙏

#TAVR #RedoTAVR #ReTAVI #revalve #ViV

[Radoslaw Parma @parma]

Transcarotid TAVI - step by step.

@PCRonline My Toolkit guide shares the Katowice 🇵🇱 workflow, from carotid exposure and dual purse-string hemostasis to valve delivery, based on >200 cases.

With W. Wojakowski, R. Gocol & D. Hudziak; commentary by @modine_thomas

#TAVI #TAVR #carotid

🔗https://t.co/rvE127s5MT

[Radoslaw Parma @parma]

#PCRCIT China Chengdu Valves left a strong impression on me. 🇨🇳

My sincere thanks to Prof. Mao Chen, his team and the #PCRCIT organizers for the warm welcome and the opportunity to see technologies that define the next chapter of structural heart disease. 🚀

An important visit for me, scientifically, professionally and personally. ⭐️

@PCRonline @nicolasdumonte1 @EmanueleBarba13 @dottormaisano @dmylotte @modine_thomas

[EAPCIPresident @EAPCIPresident]

The deadline for the the EAPCI 2027 Call for Technology & Innovation is fast approaching 🚨

We are looking for pioneering solutions that will transform cardiovascular interventions including:

⚙️ Novel devices & technologies
🤖 AI, digital health & robotics
🔬 Advanced imaging
📚 Next-gen education & training tools

There is still time to showcase your innovation on the European stage 🫀

⏳ Deadline: 1 October 2026
🔗 Submit your innovation today: https://t.co/0r2HwbdX1J

#EAPCIinnovation #EAPCI27 #EAPCIcommunity
@escardio

[Sam Tsimikas, MD @Lpa_Doc]

Hi all,
The Lp(a) HORIZON trial has released topline data and, quite shockingly, missed its primary endpoint.
In other words, lowering Lp(a) in patients with prior MI, stroke or peripheral arterial disease, who were otherwise very well treated for LDL-C, blood pressure, diabetes and other risk factors, did not reduce the primary cardiovascular endpoint.
We obviously need to see the full data before making firm conclusions, and I don’t want to speculate too much without the details.
But this is a big enough result that it is worth summarizing what we know, what we don’t know, and what this may mean for our patients after 20+ years of trying to test the “Lp(a) hypothesis.”
What we know:
1-There are hundreds if not thousands of genetic, epidemiologic and Mendelian-randomization studies showing that elevated Lp(a) is associated with MI, stroke, peripheral arterial disease and aortic stenosis. That body of evidence is very strong.
2-However, much of those data come from community-based populations, often before the era of intensive LDL-C lowering and modern secondary prevention.
3-There has been much less information about how much residual risk Lp(a) carries in someone who has already had an event and is then treated very aggressively.
4-HORIZON may have had some of the best-treated patients of any recent cardiovascular outcomes trial.
Baseline LDL-C was about 65 mg/dL, a measured LDL-C contains the cholesterol carried on Lp(a), so in reality, 15-20 points lower.
5-In patients with very high Lp(a), if you correct LDL-C for Lp(a)-cholesterol, the actual LDL-C carried by LDL particles may have been closer to 45–50 mg/dL, perhaps even lower in some patients.
6-This raises a very basic question:
Can you still demonstrate a major incremental benefit from lowering another apoB-containing particle when the underlying LDL burden has already been driven this low?

What we don’t know:
1-What was the actual corrected LDL-C in these patients? I think it would be extremely informative to directly measure Lp(a)-C and calculate corrected LDL-C. This may tell us a lot about the biological setting in which pelacarsen was being tested.
2- What was the OxPL status? Our prior work has suggested that much of the pro-inflammatory biology associated with Lp(a) is related to its enrichment in oxidized phospholipids. Did OxPL fall? Did patients with higher OxPL derive more benefit? Was Lp(a) concentration actually identifying the patients with the most pathogenic particles?
3- Did we measure the right component of Lp(a) for trial inclusion? We generally measure molar particle concentration. But is molar concentration itself the main driver of risk, or is it partly a surrogate for what the particle carries? Cholesterol? Triglycerides? Oxidized phospholipids? Other proteins? Could two patients with the same Lp(a) concentration have very different Lp(a)-mediated risk? I think this question deserves much more attention.
3- Were the genetic data telling us exactly what we thought they were telling us? The genetic data are extremely compelling, but genetics reflect lifelong exposure. A clinical trial treats patients late in life, often after decades of arterial injury and after an event has already occurred. Those are not necessarily the same experiment. Could there also be some unrecognized biology linked to the LPA locus that we have not completely accounted for? That possibility should at least be considered.
3- Does very low LDL-C modify the Lp(a) risk relationship? Maybe Lp(a) is particularly important when LDL-C is higher, but its contribution becomes smaller once LDL-C is driven to very low levels. Again, we need the data.
4- Does aspirin or other antiplatelet therapy reduce part of the risk associated with Lp(a)? Lp(a) has potentially important prothrombotic effects. Almost everyone in a trial like HORIZON is receiving contemporary antiplatelet therapy. Could that blunt one component of the risk associated with Lp(a)?
5- Why are these patients still having events? This may be one of the most interesting questions of all. These are patients with LDL-C around 65 mg/dL, and perhaps corrected LDL-C substantially lower, yet cardiovascular events continue to occur. What is driving that residual risk? Inflammation? Thrombosis? Plaque burden that is already too advanced? Other lipoprotein characteristics? Something we are not measuring?
6- Do we need to re-examine some basic assumptions about atherosclerosis? We have spent decades focusing heavily on the quantity of circulating lipoproteins. But perhaps lipoproteins are relatively benign until they undergo biological modification in the artery wall. Oxidation may be one of those key modifications. For some patients, the answer may be to remove more particles from the circulation. For others, perhaps the better approach is to prevent their oxidation or block the downstream biological effects of oxidized lipids. The recent difficulties with anti-inflammatory approaches, including IL-6 inhibition, make these mechanistic questions even more interesting.
7- Was there something specific about pelacarsen, the degree or timing of Lp(a) lowering, advanced disease, trial duration, background therapy or patient selection that mitigated a potential benefit? We simply don’t know yet. That is why the detailed results will be so important.
What does this mean for patients today?
If you have already had an MI, stroke or PAD, the immediate lesson is very clear:
1- Get all of your established risk factors treated aggressively.
2- Get LDL-C/apoB very low.
3- Control blood pressure.
4- Control diabetes.
5- Don’t smoke.
6- Use appropriate antiplatelet and other guideline-directed therapies.
HORIZON shows us what modern secondary prevention should look like.
If you have elevated Lp(a) but have never had an event, the genetic and epidemiologic data still suggest increased lifetime risk.
Until the other 4 outcome trials read out, I would continue to treat every modifiable risk factor aggressively.
We should wait for those trials before drawing broad conclusions about the entire field.
I think the story of Lp(a) therapy is beginning, not ending.
We also need to show tremendous respect and gratitude to the patients who participated in HORIZON and to the investigators and companies that invested enormous resources to actually test the Lp(a) hypothesis, to the ultimate benefit to peole with elevated Lp(a) to best guide how to manage risk.

More to come as we go forward.

[Radoslaw Parma @parma]

@DFCapodanno The Aortic stenosis study is on track still. https://t.co/r1O9mkMuKW